Rheumatology

PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM), a pioneering biotechnology firm, has unveiled promising preclinical data for an innovative treatment approach to liver fibrosis, a condition currently posing significant …